FDA ReviewedUpdated May 20, 2026

Mounjaro Guide

Mounjaro is the brand-name formulation of tirzepatide FDA-approved for type 2 diabetes, manufactured by Eli Lilly. It is prescribed weekly by injection and has become extremely popular off-label for weight loss given its superior efficacy data. Like Ozempic, Mounjaro is often prescribed for weight management while awaiting broader obesity indications.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

At a Glance

Generic NameTirzepatide
Brand NamesMounjaro
FDA StatusFDA-approved for type 2 diabetes (May 2022). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).[1]
Approval DateMay 13, 2022[1]

How Mounjaro Works

Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon. The same pathways simultaneously reduce appetite, slow gastric emptying, and appear to act directly on fat cells — producing the highest weight loss rates of any approved medication.[2][3]

Dosing Schedule

Mounjaro uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (max)

Side Effects

Common: nausea (12–18%), diarrhea (13–16%), vomiting (5–9%), constipation (5–7%), decreased appetite, abdominal pain, injection site reactions. Side effects typically improve after the first 4–8 weeks. Serious (rare): pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SURPASS-2 trial, Mounjaro (tirzepatide 15mg) reduced HbA1c by 2.46 percentage points and produced 12.4 lbs more weight loss than semaglutide 1mg. Sub-analyses showed 41% of participants achieved an HbA1c below 5.7% — essentially normal blood sugar levels.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Mounjaro

These telehealth providers offer access to tirzepatide or compounded equivalents with online consultations and home delivery.

7.5/ 10

Effecty

Best for: nationwide compounded semaglutide with brand-name fallback

★★★★☆3.8

Editorial score · methodology

$160/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Effecty review →
7.4/ 10

Navio MD

Best for: compounded tirzepatide with brand-name fallback across 48 states

★★★★☆3.7

Editorial score · methodology

$247/mo
CompoundedTirzepatideSemaglutideLegitScript Verified
Get StartedRead full Navio MD review →
7.3/ 10

altRX

Best for: Buyers who want the broadest possible brand-name FDA-approved GLP-1 access on a single platform — altRX is the only provider in the WLR directory offering all four (Mounjaro / Ozempic / Wegovy / Zepbound) alongside compounded options. Strong fit for patients who may switch between compounded and brand-name depending on response, supply, or insurance situation.

★★★★☆3.7

Editorial score · methodology

$149/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full altRX review →
7.0/ 10

Eve

Best for: **Women** seeking a women's-health-focused GLP-1 telehealth platform with dual access to either affordable compounded GLP-1 ($195/mo) OR brand-name FDA-approved Ozempic / Wegovy / Mounjaro ($1,399-$1,699/mo cash-pay), with LegitScript verification and a satisfaction guarantee. Strong fit for buyers who want a single platform supporting both ends of the compounded-vs-brand-name choice without switching providers.

★★★★☆3.5

Editorial score · methodology

$195/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Eve review →
6.8/ 10

NowPatient

Best for: Brand-name GLP-1 access without a compounded route

★★★☆☆3.4

Editorial score · methodology

$1069/mo
BrandTirzepatideSemaglutideLiraglutide
Get StartedRead full NowPatient review →
5.9/ 10

Ark Health

Best for: Buyers seeking the **broadest single-platform product menu** (compounded + brand + non-GLP-1 wellness adjuncts like Sermorelin and MIC/B12 all under one account) who can tolerate the transparency gaps (no states list, no LegitScript ID, no named pharmacy partner). NOT recommended for buyers seeking brand Ozempic/Mounjaro — direct manufacturer channels (NovoCare, LillyDirect) are 2-3× cheaper. Best value tier is the compounded oral sema at $125/mo. Note: states-served gap means buyers should call (855) 758-2275 to confirm coverage before signing up.

★★★☆☆3

Editorial score · methodology

$125/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Ark Health review →

Cost Comparison

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[5]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose and promo availability.

ProviderStarting Price
NowPatient$1069/moVisit
altRX$1249/moVisit
Navio MD$1249/moVisit
Effecty$1300/moVisit
Eve$1399/moVisit
Ark Health$1499/moVisit

Related Research on Mounjaro

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

How to Break a Weight-Loss Plateau: Honest Evidence Review
Weight-loss plateaus are predictable physiology — adaptive thermogenesis drops REE 15-20% below predicted and NEAT declines unconsciously. Six evidence-graded interventions (diet break, protein, resistance training, sleep, TDEE math, GLP-1 dose change) break most in 2-4 weeks.
11 min read11 citations
How Quickly Does Tirzepatide Work for Weight Loss? Honest Evidence Review
Tirzepatide produces appetite suppression within 1-7 days and first scale movement by week 2-4. SURMOUNT-1 reached 5% TBWL by week 12, 10% by week 24, and -20.9% peak at 72 weeks on the 15 mg dose.
9 min read9 citations
Does Anthem Cover Zepbound for Weight Loss? Honest Evidence Review
Yes on most Anthem commercial fully-insured plans with prior authorization (BMI ≥30, or ≥27 + comorbidity, plus a 3-6 month lifestyle program). Self-funded employer ASO plans may exclude weight-loss meds entirely. Medicare Advantage covers Zepbound only for the FDA-approved sleep apnea indication, not weight loss. Sourced to Anthem CC-0188, the FDA Zepbound label, SS Act §1860D-2(e)(2)(A), and the CMS Medicare GLP-1 Bridge.
10 min read11 citations
When To Drink Protein Shakes For Weight Loss? Honest Evidence Review
Timing is largely overrated. Schoenfeld 2013 meta-analysis (20 studies, 478 subjects): no timing effect on muscle outcomes when daily protein matched. Total daily dose dominates; breakfast and post-workout are the best satiety + muscle placements.
10 min read10 citations
Do Oranges Help With Weight Loss? Honest Evidence Review
Modestly yes — whole oranges (~62 kcal, 3.1 g fiber, 87% water per USDA FDC 169097) beat orange juice by a wide margin. Bertoia 2015 cohort: citrus -0.27 lb/4 yr per daily serving. Muraki 2013 BMJ: 100% OJ tied to higher T2D risk (HR 1.08) while whole fruit was protective.
9 min read12 citations
Is Yoga Good for Weight Loss? Honest Evidence Review
Yoga produces modest direct weight loss — roughly 2–3 kg in meta-analyses. Real value is stress, sleep, HRV, and lean-mass support for GLP-1 patients. Energy cost 150–400 kcal/h by style; below running, cycling, swimming.
14 min read12 citations

Frequently Asked Questions

Sources & methodology — as of May 2026
  1. 1.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SURPASS-2 Trial — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (Frías JP et al.)— New England Journal of Medicine.PMID: 34170647.
  3. 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary references

Key terms in this article, linked to their canonical definitions.